Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
431 Views
Emedinexus 02 June 2025
The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for treating Alzheimer’s disease. Kisunla is recommended for use in patients with mild cognitive impairment or mild dementia, as these were the stages studied in the clinical trials.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}